Nonmedication Devices in Development for the Treatment of Alzheimer's Disease

被引:0
作者
Sleem, Tamara [1 ]
Decourt, Boris [2 ]
Sabbagh, Marwan N. [1 ]
机构
[1] Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurol, Phoenix, AZ USA
[2] Texas Tech Univ Hlth Sci Ctr, Sch Med, Dept Pharmacol & Neurosci, Lubbock, TX USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trials; devices; treatment; DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; COGNITIVE FUNCTION; SYNAPTIC PLASTICITY; CORTEX EXCITABILITY; DOUBLE-BLIND; PHOTOBIOMODULATION; CONNECTIVITY; DEMENTIA;
D O I
10.3233/ADR-230115
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huge investments continue to be made in treatment for Alzheimer's disease (AD), with more than one hundred drugs currently in development. Pharmacological approaches and drug development, particularly those targeting amyloid-beta, have dominated the therapeutic landscape. At the same time, there is also a growing interest in devices for treating AD. This review aimed to identify and describe devices under development for AD treatment. In this review, we queried the devices that are in development for the treatment of AD. PubMed was searched through the end of 2021 using the terms "device," "therapeutics," and "Alzheimer's" for articles that report on devices to treat AD. Ten devices with 31 references were identified as actively being developed for the treatment of AD. Many of these devices are far along in development. Device-based therapies are often overlooked when evaluating treatment approaches to AD. However, many devices for treating AD are in development and some show promising results.
引用
收藏
页码:241 / 255
页数:15
相关论文
共 50 条
  • [31] A brief essay on non-pharmacological treatment of Alzheimer's disease
    Raggi, Alberto
    Tasca, Domenica
    Ferri, Raffaele
    REVIEWS IN THE NEUROSCIENCES, 2017, 28 (06) : 587 - 597
  • [32] Treatment of Alzheimer's disease
    Klimkowicz-Mrowiec, Aleksandra
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (04): : 145 - 150
  • [33] Treatment of Alzheimer's disease
    López, O
    Becker, JT
    REVISTA DE NEUROLOGIA, 2002, 35 (09) : 850 - 859
  • [34] Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia
    Szeto, Jennifer Y. Y.
    Lewis, Simon J. G.
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (04) : 326 - 338
  • [35] Alzheimer's disease drug development pipeline: 2024
    Cummings, Jeffrey
    Zhou, Yadi
    Lee, Garam
    Zhong, Kate
    Fonseca, Jorge
    Cheng, Feixiong
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (02)
  • [36] Alzheimer's disease drug development pipeline: 2021
    Cummings, Jeffrey
    Lee, Garam
    Zhong, Kate
    Fonseca, Jorge
    Taghva, Kazem
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2021, 7 (01)
  • [37] Drug development in Alzheimer's disease: the path to 2025
    Cummings, Jeffrey
    Aisen, Paul S.
    DuBois, Bruno
    Froelich, Lutz
    Jack, Clifford R., Jr.
    Jones, Roy W.
    Morris, John C.
    Raskin, Joel
    Dowsett, Sherie A.
    Scheltens, Philip
    ALZHEIMERS RESEARCH & THERAPY, 2016, 8
  • [38] The Role of Biomarkers in Alzheimer's Disease Drug Development
    Cummings, Jeffrey
    REVIEWS ON BIOMARKER STUDIES IN PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS, 2019, 1118 : 29 - 61
  • [39] Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
    Fan, Ling-Yun
    Chiu, Ming-Jang
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 439 - 451
  • [40] Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review
    Theleritis, Christos G.
    Siarkos, Kostas T.
    Politis, Antonios M.
    FRONTIERS IN PHARMACOLOGY, 2019, 10